Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

HYDROCORTISONE CREAM USP, 2.5% HYDROCORTISONE OINTMENT USP, 2.5% | Hydrocortisone

02:16 EDT 28th July 2014 | BioPortfolio
Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

FOR DERMATOLOGICAL USE ONLY

NOT FOR OPHTHALMIC USE

Rx only

DESCRIPTION

The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents. Hydrocortisone Cream 2.5% and Hydrocortisone Ointment 2.5% contain hydrocortisone. Hydrocortisone is a white to practically white crystalline powder. Chemically, hydrocortisone is pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11β)-. The structural formula of hydrocortisone is:

Each gram of the 2.5% Cream contains 25 mg of hydrocortisone in a base of glyceryl monostearate, polyoxyl 40 stearate, glycerin, paraffin, stearyl alcohol, isopropyl palmitate, sorbitan monostearate, benzyl alcohol, potassium sorbate, lactic acid and purified water.

Each gram of the 2.5% Ointment contains 25 mg of hydrocortisone in a base of white petrolatum and mineral oil.

IMAGE hydrocortisone-cream-ointment-01.jpg

CLINICAL PHARMACOLOGY

Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions.

The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.

Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (See DOSAGE AND ADMINISTRATION ).

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

INDICATIONS AND USAGE

Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

CONTRAINDICATIONS

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

PRECAUTIONS

General: Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug.

Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (See PRECAUTIONS–Pediatric Use ).

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

Information for the Patient: Patients using topical corticosteroids should receive the following information and instructions:

Laboratory tests: The following tests may be helpful in evaluating HPA axis suppression:

Urinary free cortisol test; ACTH stimulation test.

Carcinogenesis, Mutagenesis and Impairment of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.

Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

Pregnancy: Teratogenic Effects–Pregnancy Category C. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Nursing Mothers: It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

Pediatric Use: Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalamic-pituitary-adrenal (HPA) axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients.

ADVERSE REACTIONS

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.

OVERDOSAGE

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS ).

DOSAGE AND ADMINISTRATION

Apply to the affected area as a thin film 2 to 4 times daily depending on the severity of the condition.

Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

HOW SUPPLIED

Store at controlled room temperature 15° - 30°C (59° - 86°F).

E. FOUGERA & CO.

A division of Nycomed US Inc.

MELVILLE, NEW YORK 11747

I280C/IF280B #205R3/08

Hydrocortisone Cream USP, 2.5% Hydrocortisone Ointment USP, 2.5%
a white cream is available as follows: a white ointment is available as follows:
NDC 0168-0080-31 30 g tubes NDC 0168-0146-30 28.35 g (1 oz) tubes
NDC 0168-0080-16 453.6 g (1 Lb) jars NDC 0168-0146-16 453.6 g (1 Lb) jars

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 1 LB LABEL

NDC 0168-0146-16

Fougera

Rx only

HYDROCORTISONE OINTMENT USP, 2.5%

FOR DERMATOLOGICAL USE ONLY

NOT FOR OPHTHALMIC USE

NET WT 453.6 g (1 lb)

E. FOUGERA & CO.

A division of Nycomed US Inc.

Melville, New York 11747

IMAGE hydrocortisone-cream-ointment-02.jpg

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 1 OZ CONTAINER

NDC 0168-0146-30

Fougera

HYDROCORTISONE

OINTMENT USP, 2.5%

FOR DERMATOLOGICAL USE ONLY

NOT FOR OPHTHALMIC USE

Rx only

Each gram for topical administration

contains: 25 mg of hydrocortisone in

a base of white petrolatum and mineral oil.

NET WT 28.35 g (1 Oz)

IMAGE hydrocortisone-cream-ointment-03.jpg

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 1 OZ CARTON

NDC 0168-0146-30

Fougera

HYDROCORTISONE

OINTMENT USP, 2.5%

Rx only

FOR DERMATOLOGICAL USE ONLY

NOT FOR OPHTHALMIC USE

WARNING: Keep out of reach of children.

NET WT 28.35 g (1 Oz)

IMAGE hydrocortisone-cream-ointment-04.jpg

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 1 LB LABEL

NDC 0168-0080-16

Fougera

Rx only

HYDROCORTISONE CREAM USP, 2.5%

FOR DERMATOLOGICAL USE ONLY

NOT FOR OPHTHALMIC USE

NET WT 453.6 g (1 Lb)

E. FOUGERA & CO.

A division of Nycomed US Inc.

Melville, New York 11747

IMAGE hydrocortisone-cream-ointment-05.jpg

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 30 GM CONTAINER

NDC 0168-0080-31

Fougera

HYDROCORTISONE

CREAM USP, 2.5%

FOR DERMATOLOGICAL USE ONLY

NOT FOR OPHTHALMIC USE

Rx only

Each gram for topical administration

contains: 25 mg of hydrocortisone in a

base of glyceryl monostearate, polyoxyl

40 stearate, glycerin, paraffin, stearyl

alcohol, isopropyl palmitate, sorbitan

monostearate, benzyl alcohol, potassium

sorbate, lactic acid and purified water.

NET WT 30 grams

IMAGE hydrocortisone-cream-ointment-06.jpg

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 30 GM CARTON

NDC 0168-0080-31

Fougera

HYDROCORTISONE

CREAM USP, 2.5%

Rx only

FOR DERMATOLOGICAL USE ONLY

NOT FOR OPHTHALMIC USE

WARNING: Keep out of reach of children.

NET WT 30 grams

IMAGE hydrocortisone-cream-ointment-07.jpg

Manufacturer

E. FOUGERA & CO. A division of Nycomed US Inc.

Active Ingredients

Source

Drugs and Medications [273 Associated Drugs and Medications listed on BioPortfolio]

Rexall hydrocortisone 1 [Dolgencorp, LLC]

Dolgencorp, LLC Hydrocortisone 1% Cream Drug Facts

Hydrocortisone 1 [CVS Pharmacy]

CVS Pharmacy, Inc. Hydrocortisone 1% Drug Facts

Rodan and fields [Cosmetic Enterprises Ltd.]

Soothe

Hydrocortisone [H E B]

HEB 1% Hydrocortisone Ointment Drug Facts

Hydrocortisone [B8 Sales, Inc.]

PIO Put it on®1% Hydrocortisone Cream™

Clinical Trials [97 Associated Clinical Trials listed on BioPortfolio]

Hydrocortisone in the Treatment of Intrusions in Patients With Posttraumatic Stress Disorder

To test overall efficacy of hydrocortisone on reexperience of traumatic memories (intrusions) and overall symptomatology in patients meeting criteria of complex chronic PTSD.

Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?

The primary purpose of this study is to examine whether IV hydrocortisone can speed up the time required for Venlafaxine XR to work.

Rapid Effects of Hydrocortisone on Glucose-Induced Insulin Secretion in Healthy Humans

The purpose of this study is to investigate the effect of hydrocortisone on glucose-induced insulin secretion and sensitivity, by means of an intravenous glucose tolerance test with freque...

Once-Daily Oral Modified-Release Hydrocortisone in Patients With Adrenal Insufficiency

This is a randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral modifie...

Hydrocortisone for Prevention of Septic Shock

Severe sepsis is a disease with a high mortality. Development of shock is a most serious complication and increases the risk of death considerably. Application of low dose hydrocortisone i...

PubMed Articles [33 Associated PubMed Articles listed on BioPortfolio]

Fludrocortisone and hydrocortisone, alone or in combination, on in vivo hemodynamics and in vitro vascular reactivity in normal and endotoxemic rats: a randomized factorial design study.

Hydrocortisone enhances the pressor response to catecholamines in healthy volunteers and septic shock patients. Similar data do not exist for fludrocortisone. We assessed the effects of single adminis...

Hair Cortisol Measurement in Mitotane-Treated Adrenocortical Cancer Patients.

The only approved drug for the treatment of adrenocortical cancer (ACC) is mitotane. Mitotane is adrenolytic and therefore, hydrocortisone replacement therapy is necessary. Since mitotane increases co...

Low-dose hydrocortisone therapy attenuates septic shock in adult patients but does not reduce 28-day mortality: a meta-analysis of randomized controlled trials.

The role of low-dose hydrocortisone in attenuating septic shock and reducing short-term mortality in adult patients with septic shock is unclear. We conducted a meta-analysis of previous studies to de...

Validation of a thin-layer chromatography for the determination of hydrocortisone acetate and lidocaine in a pharmaceutical preparation.

A new specific, precise, accurate, and robust TLC-densitometry has been developed for the simultaneous determination of hydrocortisone acetate and lidocaine hydrochloride in combined pharmaceutical fo...

Hydrocortisone normalizes phosphodiesterase-5 activity in pulmonary artery smooth muscle cells from lambs with persistent pulmonary hypertension of the newborn.

Phosphodiesterase-5 (PDE5) is the primary phosphodiesterase in the pulmonary vasculature. It degrades cyclic guanosine monophosphate (cGMP) and inhibits cGMP-mediated vasorelaxation. We previously rep...

Search BioPortfolio:
Advertisement

Relevant Topic

Dermatology
Latest News Clinical Trials Research Drugs Reports Corporate
Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers a range of diseases including skin allergies, alopecia, Behcet'...

Advertisement

Drugs and Medication Quicklinks


Searches Linking to this Drug Record